In the context of cancer therapy, where immune checkpoint inhibitors, such as ipilimumab, nivolumab, and pembrolizumab, have proven effective [37,38], we observed that Wnt pathway activity significantly correlated with CTLA-4 expression, a key marker of response to these therapies. The gene discussed is CTLA4; the disease is cancer.